These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28978885)

  • 1. [Avoidance of platelet transfusion with readministration of lusutrombopag before radiofrequency ablation in hepatocellular carcinoma:a case report].
    Kotani S; Kohge N; Tsukano K; Ogawa S; Yamanouchi S; Kusunoki R; Aimi M; Miyaoka Y; Fujishiro H
    Nihon Shokakibyo Gakkai Zasshi; 2017; 114(10):1853-1859. PubMed ID: 28978885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
    Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Shimizu T; Watakabe K; Enomoto N; Izumi N
    PLoS One; 2019; 14(2):e0211122. PubMed ID: 30768601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
    Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1192-1200. PubMed ID: 30502505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient.
    Sakamaki A; Watanabe T; Abe S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
    Clin J Gastroenterol; 2017 Jun; 10(3):261-264. PubMed ID: 28324272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
    Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    J Gastroenterol; 2019 Feb; 54(2):171-181. PubMed ID: 30105510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational study.
    Yoshida H; Ohki T; Kanezaki M; Teratani T; Sato S; Obi S; Sato T; Akamatsu M; Uchino K; Taniguchi H
    BMC Gastroenterol; 2023 Jul; 23(1):250. PubMed ID: 37488476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.
    Sato S; Miyake T; Kataoka M; Isoda K; Yazaki T; Tobita H; Ishimura N; Kinoshita Y
    Intern Med; 2017 Nov; 56(21):2887-2890. PubMed ID: 28943563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lusutrombopag Reduces the Risk of Hemoperitoneum Caused by Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Compared with Platelet Transfusion.
    Taki S; Ida Y; Tamai H; Maeshima S; Shimizu R; Shingaki N; Maekita T; Iguchi M; Kitano M
    Dig Dis; 2024 Apr; ():1-7. PubMed ID: 38663358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia.
    Ishikawa T; Okoshi M; Tomiyoshi K; Kojima Y; Horigome R; Imai M; Nozawa Y; Iwanaga A; Sano T; Honma T; Yoshida T
    Hepatol Res; 2019 May; 49(5):590-593. PubMed ID: 30602063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma.
    Alkhouri N; Imawari M; Izumi N; Osaki Y; Ochiai T; Kano T; Bentley R; Trevisani F
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2600-2608.e1. PubMed ID: 32205226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series.
    Biolato M; Vitale F; Marrone G; Miele L; Grieco A
    Medicine (Baltimore); 2022 Nov; 101(44):e31429. PubMed ID: 36343065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy].
    Hirashita T; Nakashima K; Sakai M; Sakai I
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1123-6. PubMed ID: 17637554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
    Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Tanaka T; Sunago K; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Abe M; Joko K; Michitaka K; Hiasa Y
    J Gastroenterol Hepatol; 2020 Feb; 35(2):299-304. PubMed ID: 31318996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous radiofrequency ablation of hepatocellular carcinoma in cirrhosis: analysis of complications in a single centre over 20 years.
    Giorgio A; Merola MG; Montesarchio L; Merola F; Gatti P; Coppola C; Giorgio V; Calisti G
    Br J Radiol; 2017 Jun; 90(1074):20160804. PubMed ID: 28402124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
    Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
    Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two cases of liver cirrhosis treated with lusutrombopag before partial splenic embolization.
    Fujita M; Abe K; Hayashi M; Okai K; Takahashi A; Ohira H
    Fukushima J Med Sci; 2017 Dec; 63(3):165-171. PubMed ID: 29142151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis.
    Raut CP; Izzo F; Marra P; Ellis LM; Vauthey JN; Cremona F; Vallone P; Mastro A; Fornage BD; Curley SA
    Ann Surg Oncol; 2005 Aug; 12(8):616-28. PubMed ID: 15965731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function.
    Takeuchi H; Furuichi Y; Yoshimasu Y; Kasai Y; Abe M; Sugimoto K; Itoi T
    J Nippon Med Sch; 2021 Jan; 87(6):325-333. PubMed ID: 32238734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pre-operative platelet transfusion algorithm for patients with cirrhosis and hepatocellular carcinoma undergoing laparoscopic microwave ablation.
    Baimas-George M; Watson M; Salibi P; Murphy KJ; Vrochides D; Martinie JB; Baker EH; Iannitti DA
    Surg Endosc; 2021 Jul; 35(7):3811-3817. PubMed ID: 32632482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Platelet Count on Perioperative Bleeding in Patients With Cirrhosis Undergoing Surgical Treatments of Liver Cancer.
    Ronca V; Barabino M; Santambrogio R; Opocher E; Hodson J; Bertolini E; Birocchi S; Piccolo G; Battezzati P; Cattaneo M; Podda GM
    Hepatol Commun; 2022 Feb; 6(2):423-434. PubMed ID: 34716696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.